Wyoming Chapter of the American College of Cardiology

Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.

For more information and to register, please visit: ACC Rockies Chapter Meeting 2026

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

Latest in Cardiology from ACC.org

TAVR vs. SAVR: Outcomes Differ By Sex and Over Time
TAVR outcomes differ by sex and vary over time, with women seeing an early benefit with TAVR vs. SAVR that converged by year five and men exhibiting no significant differences across time points, according to a meta-analysis of nine randomized trials published June 10 in JACC: Advances.
AI-Enabled Clinician: Building Clinical Autonomy with Large Language Models
In this episode, Chief Innovation Officer Dr. Ami Bhatt and Dr. Katie Berlacher discuss how large language models (LLMs) can be integrated into clinical workflows and medical education while preserving clinical autonomy.
CMS Releases Resources For ACCESS Model Implementation
The Centers for Medicare and Medicaid Services' (CMS') new Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model will begin July 5, 2026.
ACC CardiaCast: Treating PSVT
This episode is part of ACC's ongoing educational initiative to enhance the recognition, diagnosis, and management of paroxysmal supraventricular tachycardia (PSVT).
21-Year DPP Follow-Up: Lifestyle Intervention, But Not Metformin, Lowers Multimorbidity Risk in Prediabetes
An intensive lifestyle intervention was associated with a lower long-term burden of multimorbidity among adults with prediabetes, while metformin was not associated with a statistically significant reduction vs. placebo, according to a 21-year follow-up analysis of the Diabetes Prevention Program...